Key facts
- DMC Biotechnologies’s last known valuation is $104.0M (Dec 2021).
- It has raised $55.0M across 6 recorded rounds; the latest was Seed Round ($1.4M) in Dec 2025.
- Notable investors include US National Science Foundation, U.S. Department of Energy, Breakthrough Energy, United States Department of Agriculture, Sofinnova Partners — 22 tracked in total.
- DMC Biotechnologies has filed 7 Form Ds with the SEC since 2018, most recently Apr 2025 ($4.8M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for DMC Biotechnologies
Funding rounds
6 roundsAbout DMC Biotechnologies
Developer of bio-based chemicals designed for low-cost, sustainable transformation of multiple product markets. The company's chemicals use engineered microbes for enhanced fermentation instead of extracting ingredients from finite agricultural resources that are subject to extreme weather and climate change, enabling clients to reduce biological complexity enhance the speed of development, and grow sustainably.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2014
- Employees
- 51
- Website
- dmcbio.com/
- Ownership
- Privately Held (backing)
DMC Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DMC Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DMC Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.